136 related articles for article (PubMed ID: 11861400)
1. Human tumor suppressor ARF impedes S-phase progression independent of p53.
Yarbrough WG; Bessho M; Zanation A; Bisi JE; Xiong Y
Cancer Res; 2002 Feb; 62(4):1171-7. PubMed ID: 11861400
[TBL] [Abstract][Full Text] [Related]
2. The Pezcoller lecture: cancer cell cycles revisited.
Sherr CJ
Cancer Res; 2000 Jul; 60(14):3689-95. PubMed ID: 10919634
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis.
Hemmati PG; Gillissen B; von Haefen C; Wendt J; Stärck L; Güner D; Dörken B; Daniel PT
Oncogene; 2002 May; 21(20):3149-61. PubMed ID: 12082630
[TBL] [Abstract][Full Text] [Related]
4. Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways.
Weber HO; Samuel T; Rauch P; Funk JO
Oncogene; 2002 May; 21(20):3207-12. PubMed ID: 12082636
[TBL] [Abstract][Full Text] [Related]
5. The alternative reading frame tumor suppressor inhibits growth through p21-dependent and p21-independent pathways.
Modestou M; Puig-Antich V; Korgaonkar C; Eapen A; Quelle DE
Cancer Res; 2001 Apr; 61(7):3145-50. PubMed ID: 11306500
[TBL] [Abstract][Full Text] [Related]
6. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements.
D'Amico M; Wu K; Fu M; Rao M; Albanese C; Russell RG; Lian H; Bregman D; White MA; Pestell RG
Cancer Res; 2004 Jun; 64(12):4122-30. PubMed ID: 15205322
[TBL] [Abstract][Full Text] [Related]
7. E2F activity is essential for survival of Myc-overexpressing human cancer cells.
Santoni-Rugiu E; Duro D; Farkas T; Mathiasen IS; Jäättelä M; Bartek J; Lukas J
Oncogene; 2002 Sep; 21(42):6498-509. PubMed ID: 12226753
[TBL] [Abstract][Full Text] [Related]
8. Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control.
Hasan MK; Yaguchi T; Minoda Y; Hirano T; Taira K; Wadhwa R; Kaul SC
Biochem J; 2004 Jun; 380(Pt 3):605-10. PubMed ID: 15109303
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitination of, and sumoylation by, the Arf tumor suppressor.
den Besten W; Kuo ML; Tago K; Williams RT; Sherr CJ
Isr Med Assoc J; 2006 Apr; 8(4):249-51. PubMed ID: 16671360
[TBL] [Abstract][Full Text] [Related]
10. Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation.
Pérez de Castro I; Benet M; Jiménez M; Alzabin S; Malumbres M; Pellicer A
Cancer Res; 2005 Apr; 65(8):3249-56. PubMed ID: 15833857
[TBL] [Abstract][Full Text] [Related]
11. p53-Dependent and -independent functions of the Arf tumor suppressor.
Sherr CJ; Bertwistle D; DEN Besten W; Kuo ML; Sugimoto M; Tago K; Williams RT; Zindy F; Roussel MF
Cold Spring Harb Symp Quant Biol; 2005; 70():129-37. PubMed ID: 16869746
[TBL] [Abstract][Full Text] [Related]
12. Over-expression of CDKIs p15INK4b, p16INK4a and p21CIP1/WAF1 genes mediate growth arrest in human osteosarcoma cell lines.
Agiostratidou G; Derventzi A; Gonos ES
In Vivo; 2001; 15(5):443-6. PubMed ID: 11695244
[TBL] [Abstract][Full Text] [Related]
13. p53 mediates density-dependent growth arrest.
Meerson A; Milyavsky M; Rotter V
FEBS Lett; 2004 Feb; 559(1-3):152-8. PubMed ID: 14960324
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
[TBL] [Abstract][Full Text] [Related]
15. Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc.
Haviernik P; Schmidt M; Hu X; Wolff L
Oncogene; 2003 Mar; 22(11):1600-10. PubMed ID: 12642863
[TBL] [Abstract][Full Text] [Related]
16. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck.
Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Aug; 441(2):133-42. PubMed ID: 12189502
[TBL] [Abstract][Full Text] [Related]
17. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis.
Sharpless NE; Ramsey MR; Balasubramanian P; Castrillon DH; DePinho RA
Oncogene; 2004 Jan; 23(2):379-85. PubMed ID: 14724566
[TBL] [Abstract][Full Text] [Related]
18. Correlation between p14(ARF)/p16(INK4A) expression and HPV infection in uterine cervical cancer.
Kanao H; Enomoto T; Ueda Y; Fujita M; Nakashima R; Ueno Y; Miyatake T; Yoshizaki T; Buzard GS; Kimura T; Yoshino K; Murata Y
Cancer Lett; 2004 Sep; 213(1):31-7. PubMed ID: 15312681
[TBL] [Abstract][Full Text] [Related]
19. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG
Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676
[TBL] [Abstract][Full Text] [Related]
20. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
